Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: A long-term analysis based on the CURE trial

Canadian Journal of Cardiology

Volumn 23, Issue 13, 2007, Pages 1037-1042

  Kolm, Paul ^a   Yuan, Yong ^b   Veledar, Emir ^c   Mehta, Shamir R ^d   O'Brien, Judith A ^e   Weintraub, William S ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c EMORY UNIVERSITY   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e CARO RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet therapy; Case Mix Group classification; Cost effectiveness; Outcomes

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BOOTSTRAPPING; CANADA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE CLASSIFICATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HOSPITALIZATION COST; HUMAN; LIFE EXPECTANCY; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COMBINATION; ECONOMICS; HOSPITALIZATION; LENGTH OF STAY; MIDDLE AGED; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CANADA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LIFE EXPECTANCY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; TICLOPIDINE; TIME FACTORS;

EID: 38449086326     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70870-X     Document Type: Article

References (16)

1. Heart and Stroke Foundation of Canada. The growing burden of heart disease and stroke in Canada, 2003. (Version current at September 26, 2007).
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable angina to prevent Recurrent Events trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Errata in 2001;345:1506, 2001;345:1716).
3. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-33.
4. Weintraub WS, Mahoney EM, Lamy A, et al; CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005;45:838-45.
5. Lamy A, Jönsson B, Weintraub WS, et al; The CURE Economic Group. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil 2004;11:460-5.
6. Health Funding and Costing Branch, Alberta Health and Wellness. Health costing in Alberta, 2003 - annual report. (Version current at September 26, 2007).
7. The Institute of Health Economics. Provincial and national cost per weighted case for inpatient services for fiscal year 2000/1. (Version current at September 26, 2007).
8. Statistics Canada. Latest release from the Consumer Price Index. .
9. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology, 3rd edn. Chichester: Wiley, 2000:325-45.
10. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: A case study in atherothrombosis. Value Health 2004;7:627-35.
11. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993.
12. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458-66.
13. Mahoney EM, Jurkovitz CT, Chu H, et al; TACTICS-TIMI 18 Investigators. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy - Thrombolysis in Myocardial Infarction. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851-8.
14. Spaans JN, Coyle D, Fodor G, et al. Application of the 1998 Canadian cholesterol guidelines to a military population: Health benefits and cost effectiveness of improved cholesterol management. Can J Cardiol 2003;19:790-6.
15. Lamy A, Yusuf S, Pogue J, Gafni A; Heart Outcomes Prevention Evaluation Investigators. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003;107:960-5.
16. Canadian Coordinating Office of Health Technology Assessment. HMG-CoA reductase inhibitors: A review of published clinical trials and pharmacoeconomic evaluations. (Version current at September 26, 2007).